BioRestorative Therapies (BRTX) announced that its Board of Directors has authorized a stock repurchase program under which the Company may repurchase up to $2M of its outstanding common stock through June 16, 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRTX:
- Promising Outlook for BioRestorative Therapies: Buy Rating Supported by Positive BRTX-100 Data and FDA Fast Track Designation
- BioRestorative Reports Promising Phase 2 Trial Results
- BioRestorative Therapies reports preliminary data from Phase 2 trial of BRTX-100
- BioRestorative Therapies appoints Sandy Lipkins for business development
- Positive Outlook for BioRestorative Therapies: Advancements in Clinical Trials and Financial Stability Drive Buy Rating